JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Benitec Biopharma (BNTC – Research Report) today and set a price target of $4.00. The company’s shares opened today at $0.23.
Tuerkcan covers the Healthcare sector, focusing on stocks such as Mirati Therapeutics, Vor Biopharma, and Cellectis SA. According to TipRanks, Tuerkcan has an average return of 1.9% and a 36.24% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Benitec Biopharma with a $4.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Benitec Biopharma’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.09 million. In comparison, last year the company had a GAAP net loss of $5.05 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Benitec Biopharma Ltd. engages in the development of proprietary therapeutic technology platform. It focuses on chronic and life-threatening human disease areas such as oncology, orphan disease, retinal disease, and infectious disease. The company was founded in 1997 and is headquartered in North Sydney, Australia.
Read More on BNTC:
